Overview
Cardiac-valvular Ehlers-Danlos syndrome (cvEDS), also known as Ehlers-Danlos syndrome cardiac valvular type, is an extremely rare heritable connective tissue disorder characterized by severe progressive cardiac valvular problems, joint hypermobility, and skin hyperextensibility. It is caused by biallelic (homozygous or compound heterozygous) pathogenic variants in the COL1A2 gene, which encodes the pro-alpha-2 chain of type I collagen. The resulting complete absence of the pro-alpha-2(I) collagen chain leads to the production of abnormal type I collagen homotrimers composed solely of alpha-1(I) chains, which disrupts connective tissue integrity throughout the body. The hallmark feature of cvEDS is severe cardiac valvular disease, particularly affecting the aortic and mitral valves, which may progress to require surgical valve replacement. Patients typically present with joint hypermobility (both generalized and small joint), skin hyperextensibility, skin fragility with atrophic scarring, and easy bruising. Additional features may include inguinal hernias, pectus deformity, joint dislocations, and foot deformities. The cardiac valvular involvement distinguishes this subtype from other forms of Ehlers-Danlos syndrome and represents the most clinically significant and potentially life-threatening aspect of the condition. There is currently no cure or disease-specific therapy for cvEDS. Management is supportive and multidisciplinary, focusing on regular cardiac surveillance with echocardiography to monitor valvular function, surgical intervention for severe valvular insufficiency when indicated, physical therapy to support joint stability, and skin protection measures. Genetic counseling is recommended for affected families. Due to the extreme rarity of this condition, clinical experience is limited, and management guidelines are largely based on expert consensus and extrapolation from other Ehlers-Danlos syndrome subtypes.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Cardiac-valvular Ehlers-Danlos syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Cardiac-valvular Ehlers-Danlos syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Cardiac-valvular Ehlers-Danlos syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Cardiac-valvular Ehlers-Danlos syndrome.
Community
No community posts yet. Be the first to share your experience with Cardiac-valvular Ehlers-Danlos syndrome.
Start the conversation →Latest news about Cardiac-valvular Ehlers-Danlos syndrome
No recent news articles for Cardiac-valvular Ehlers-Danlos syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Cardiac-valvular Ehlers-Danlos syndrome
What is Cardiac-valvular Ehlers-Danlos syndrome?
Cardiac-valvular Ehlers-Danlos syndrome (cvEDS), also known as Ehlers-Danlos syndrome cardiac valvular type, is an extremely rare heritable connective tissue disorder characterized by severe progressive cardiac valvular problems, joint hypermobility, and skin hyperextensibility. It is caused by biallelic (homozygous or compound heterozygous) pathogenic variants in the COL1A2 gene, which encodes the pro-alpha-2 chain of type I collagen. The resulting complete absence of the pro-alpha-2(I) collagen chain leads to the production of abnormal type I collagen homotrimers composed solely of alpha-1(I
How is Cardiac-valvular Ehlers-Danlos syndrome inherited?
Cardiac-valvular Ehlers-Danlos syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.